Clinical Trials Links:
Practice Information:
The following clinical trials are open to patients with anaplastic astrocytoma:
Recurrent Anaplastic Astrocytoma
Compassionate Use Trial of Temodol in Recurrent Malignant Glioma.
Eligibility: Recurrent Malignant Glioma.
Protocol: Temodal, an oral agent, is taken five days out of each 4 week period.
Newly Diagnosed Anaplastic Astrocytoma
Phase II study of High-Dose Carboplatin Prior to Radiation Therapy
Eligibility: Newly diagnosed anaplastic astrocytoma, glioblastoma multiforme
Protocol: up to four cycles of Carboplatin are given prior to the administration of local field radiation therapy. Follow-up chemotherapy is then given.
Recurrent Anaplastic Astrocytoma
Phase I/II dose escalation study of Carboplatin and Thalidomide in recurrent high grade glioma
Eligibility: Recurrent high grade glial neoplasm, no prior carboplatin or cisplatinum based chemotherapy.
Protocol: Carboplatin is administered monthly and Thalidomide is administered daily. Up to six courses of therapy may be given.
Newly Diagnosed or Anaplastic Astrocytoma
Phase II study of high-dose Carboplatin/Thiotepa with autologous stem-cell support in newly diagnosed or recurrent high grade glioma
Eligibility: Newly diagnosed or recurrent high grade glial neoplasm, No prior Thiotepa, Carboplatin, or Cisplatinum based chemotherapy.
Protocol: Following stem-cell harvest, high-dose Carboplatin and Thiotepa are administered followed by stem cell re-infusion. Two cycles of therapy are given.
Recurrent Anaplastic Astrocytoma
Phase II study of high-dose Cyclophosphamide/Etoposide with gCSF support in recurrent high grade glioma
Eligibility: Recurrent high grade glial neoplasm, No prior Cyclophosphamide or Etoposide, and failure of radiation therapy and carboplatin-based chemotherapy.
Protocol: high-dose Cyclophosphamide and Etoposide are followed by gCSF support. Treatment is repeated as tolerated.